medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2017, Number 09

<< Back Next >>

Ginecol Obstet Mex 2017; 85 (09)

Uterine myomatosis: Implications on reproductive health

Ruiz-Sánchez E, Peinado-Rodenas J, Castillo-Cañadas AM, Paucar-Espinal G, González MG

Language: Spanish
References: 61
Page: 611-633
PDF size: 469.12 Kb.


ABSTRACT

Objetive: To make known to the gynecological obstetricians a document where they can be consulted, in the light of the most recent studies and with the best evidence on the pathophysiology, prevalence and clinical significance of uterine fibroids, as well as the best possible evidence about the various treatment modalities.
Methodology: A retrospective study carried out by the members of the Committee of experts of the Mexican Association of Reproductive Medicine, using the articles published between 2000 and 2016 in Pubmed and that in the abstract contained MeSH: leiomyomatosis uterus, leiomyoma, Leiomyomatosis uterine, leiomyomatosis uterine in pregnancy. The quality of the evidence and the formulation of the recommendations were made using the methodology established by the GRADE system.
Results: 97 articles were included in which the prevalence was found to be variable, according to age (20 to 80%) in women of reproductive age. In most, the diagnosis is established between 35 and 54 years. There are several treatment options with different percentages of effectiveness.
Conclusions: Evidence of the efficacy of several medications indicated for the control of symptoms and to improve the quality of life of the patients is evident. In the comparison between leuprolide acetate and ulipristal acetate, they were not found to cause vasomotor symptoms or to decrease bone mass. Regarding the latter, the possibility of avoiding surgery is envisaged, although more research is still needed in this regard.


REFERENCES

  1. Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future, Human Reproduction Update 2016:1-22.

  2. Bulun SE. Uterine Fibroids. N Engl J Med 2013;369:14.

  3. Lauren A, Wise MSC, Laughlin-Tommaso SK. Epidemiology of Uterine Fibroids: From Menarche to Menopause. Clini Obstetrics and gynecology 2016;59(1).

  4. Manyonda IT. Medical management of fibroids. Best Practice & Research Clinical Obstetrics and Gynecology 2008;22(4):655-676.

  5. Xinmei Zhang, M.D., Bangchun Lu, M.D., Xiufeng Huang, M.D., Hong Xu, M.D., Caiyun Zhou, M.D., and Jun Lin, M.D., Innervation of endometrium and myometrium in women with painful adenomyosis and uterine fibroids, Fertility and Sterility Vol. 94, No. 2, July 2010.

  6. Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344- 1355. (Revisión10. Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344-1355. (Revisión).

  7. Ortiz RME, Matute LA, Martínez CN. Miomatosis uterina. An Med 2009;54:222-233 (Revisión).

  8. Kim JJ, Elizabeth C. Sefton, The role of progesterone signaling in the pathogenesis of uterine leiomyoma, Molecular and Cellular Endocrinology 358 (2012) 223–231.

  9. Andrea Ciavattini, Jacopo Di Giuseppe, Piergiorgio Stortoni, Nina Montik, Stefano R. Giannubilo and Pietro Litta. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstetrics and Gynecology International. (Annual 2013).

  10. Paul J. Hoffman, B.S., Dawn B. Milliken, B.S., Laurie C. Gregg, M.D., Ryan R. Davis, B.S., and Jeffrey P. Gregg, M.D. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. FERTILITY AND STERILITY VOL. 83, NO. 3, SEPTEMBER 2004.

  11. Nathalie Chabbert-Buffet, M.D., Ph.D., Nathalie Esber, M.Sc., and Philippe Bouchard, M.D. Fibroid growth and medical options for treatment. Fertil Steril 2014;102: 2014 by American Society for Reproductive Medicine

  12. Joaquín Calaf, Maria Arqué, Oriol Porta y Emanuela D’Angelo. El mioma como problema clínico. Med Clin (Barc). 2013;141(Supl 1):1-6.

  13. Masanori Ono, Wenan Qiang, Vanida Ann Serna, Ping Yin, John S. Coon V, Antonia Navarro, Diana Monsivais, Toshiyuki Kakinuma, Matthew Dyson, Stacy Druschitz, Kenji Unno, Takeshi Kurita, Serdar E. Bulun, Role of Stem Cells in Human Uterine Leiomyoma Growth. PLoS ONE 7(17): e36935. doi:10.1371/ journal.pone.0036935, May 2012 | Volume 7 | Issue 5 | e36935.

  14. Shilpa Bhandari, Ishita Ganguly, Pallavi Agarwal, Aparna Singh, Nitika Gupta Effect of myomectomy on endometrial cavity: A prospective study of 51 cases. Journal of Human Reproductive Sciences, Volume 9, Issue 2, Apr - Jun 2016.

  15. Sara M. Drayer , William H. Catherino, Prevalence, morbidity, and current medical management of uterine leiomyomas, International Journal of Gynecology and Obstetrics 131 (2015) 117–122

  16. Bruce D. Pier and G. Wright Bates, Potential causes of subfertility in patients with intramural fibroids. Fertility Research and Practice (2015) 1:12.

  17. Kinza Younas MBBS MRCOG MD, Essam Hadoura MRCOG MB ChB, Franz Majoko MBBS MRCOG PhD, d, Adnan Bunkheila. A review of evidence-based management of uterine fibroids. The Obstetrician & Gynaecologist 2016;18:33–42.

  18. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87:725–736. Nelson AL, Ritchie JJ. Severe anemia from heavy menstrual bleeding requires heightened attention. Am J Obstet Gynecol 2015;213:97.

  19. Molly B. Moravek and Serdar E. Bulun, Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. Curr Opin Obstet Gynecol 2015, 27:276–283.

  20. Lippman SA,WarnerM, Samuels S, et al.Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril. 2003;80: 1488–1494.

  21. Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health 2012;12:6 Ferrero S, Abbamonte LH; Uterine myomas, dyspareunia, and sexual function. Fertil Steril. 2006;86(17):1504.

  22. Zepiridis LI, Grimbizis GF, Tarlatzis BC. Infertility and uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2015;S1521- 6934:00235-00237.

  23. Cakmak H, Taylor HS. Implantation failure: molecular mechanisms and clinical treatment. Hum Reprod Update. 2011;17:242–53. Ben-Nagi J, Miell J, Mavrelos D, Naftalin J, Lee C, Jurkovic D. Endometrial implantation factors in women with submucous uterine fibroids. Reprod Biomed Online. 2010;21:610–5.

  24. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Ob¬stet Gynecol. 2003;188(1):100-107.

  25. Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids; an international internet-based survey of 21,746 women. BMC Womens Health 2012;12:6. Available at: http://www.biomedcentral.com/1472-6874/12/6.

  26. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87(4):725-736.

  27. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424-30.

  28. Sinclair DC, Mastroyannis A, TaylorHS. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-beta3. J Clin Endocrinol Metab 2011;96:412-21.

  29. Pritts EA, Parker WH, Olive DL. Fibroids and infertil¬ity: an updated systematic review of the evidence. Fertil Steril. 2009;91(4):1215-1223.

  30. 7. Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature re¬view from conception to delivery. Am J Obstet Gynecol. 2008;198(4):357-366.

  31. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myo¬mectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;(2):CD000547.

  32. Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature re¬view from conception to delivery. Am J Obstet Gynecol. 2008;198(4):357-366.

  33. Trefoux Bourdet A, Luton D, Koskas M. Clinical utility of ulipristal acetate for the treatment of uterine fibroids; current evidence. Int J Womens Health 2015; 7: 321–330. Revisión.

  34. Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421-432. double-blind noninferiority trial, we randomly assigned

  35. Beth W, Aydin A. Options for medical treatment of myomas. Obstet Gynecol Clin N Am 2006;33:97-113

  36. Donnez J, Dolmans M-M. Uterine fibroid management: from the present to the future. Human Reprod Update 2016; 1-22. Revisión.

  37. Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BCJM, Barlow DH, Palacios S, Donnez O. Longterm treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565–1573. Repeated intermittent open-label UPA courses, each followed by randomized double-blind norethisterone acetate (NETA) or placebo.

  38. Donnez J, Hudecek R, Donnez O, Matule D, Ahrendt H-J, Zatik J, Kasilovskiene Z, Dumitrascu MC. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519–527. Double-blind, randomized

  39. Donnez J, Donnez O, Matule D, Ahrendt H-J, Hudecek R, Zatik J, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH, Bouchard P, Fauser BCJM, Bastel E, Loumaye E. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016; 105: 165–173. Double-blind, randomized

  40. De Falco M, Staibano S, Mascolo M, Mignogna C, Improda I, Ciociola F, et al. Leiomyoma pseudocapsule after pre surgical treatment with gonadotropin-releasing hormone agonists: relatioship betwen clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod biol 2009;144:44-7.

  41. Frederick S, Frederick J, Fletcher H, Reid M, Hardie M, Gardner W. A trial comparing the use of rectal misoprostol plus perivascular vasopressin with perivascular vassopressin alone to decrease miometrial bleeding at the time of abdominal myomectomy. Fertil Steril 2013;100:1044-9

  42. Shokeir TA. Hysteroscopic management in submucous fibroids to improve fertility. Arch Gynecol Obstet 2005;273:50-4.

  43. Zupi E, Piredda A, Marconi D, Townsend D, Exacoustos C, Arduini D, Szabolcs B. Directed laparoscopic cryomyolysis: a possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. Am J Obstet Gynecol. 2004;190(3):639.

  44. Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol. 1997;89(5 Pt 2):857.

  45. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104(2):393.)

  46. American Association of Gynecologic Laparoscopists (AAGL). Practice report: practice guidelines for laparoscopic/ subtotal supracervical hysterectomy. J Min Invas Gynecol 2014;21:9-16.

  47. García CR. Management of the symptomatic fibroid in women older than 40 years of age: hysterectomy or myomectomy? Obstet Clin North Am 1993;20:337-48

  48. Practice Committee of the American Society for Reproductive Medicine; Society for Reproductive Surgeons. Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery. Fertil Stril 2007;88:21-6.

  49. Bocca S, Stadtmauer L, Oehninger S. Uncomplicated full term pregnancy after da Vinci-assisted laparoscopic myomectomy. Reprod Biomed Online. 2007;14(2):246.

  50. Lönnerfors C, Persson J .Pregnancy following robot-assisted laparoscopic myomectomy in women with deep intramural myomas. Acta Obstet Gynecol Scand. 2011 Sep;90(9):972- 7. Epub 2011 Jul 20.

  51. Ordulu Z, Dal cin P, Chong WWS, Choy KW, Lee C, Muto MG, et al. Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomioma. Genes Chromosomes Cancer 2010;49:1152-60

  52. Ribic-Pucelj M, Cvjeticanin B, Salamun V. Leiomyomatosis peritonealis disseminata as a posible result of laparoscopic myomectomy- report of four cases. Gynecol Surg 2013;10:253-6

  53. Derman SG, Rehnstrom J, Neuwirth RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol. 1991;77(4):591.

  54. Hald K, Kløw NE, Qvigstad E, Istre O . Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol. 2007;109(1):20.

  55. Vilos GA, Vilos EC, Romano W, Abu-Rafea B. Temporary uterine artery occlusion for treatment of menorrhagia and uterine fibroids using an incisionless Dopplerguided transvaginal clamp: case report. Hum Reprod. 2006;21(1):269.

  56. Gupta JK, Sinha AS, Lumsden MA, Hickey M Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2006

  57. Van der Kooij SM, Bipat S, Hehenkamp WJ, Ankum WM, Reekers JA. Uterine artery embolization versus surgery in the treatment of symptomatic fibroids: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011 Oct;205(4):317. e1-18. Epub 2011 Mar 16.58. Funaki K, Fukunishi H, Sawada K. Clinical outcomes of magnetic resonance-guided focused ultrasound surgery for uterine myomas: 24-month followup. Ultrasound Obstet Gynecol. 2009;34(5):584.

  58. Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol. 2007;110(2 Pt 1):279.

  59. Rabinovici J, David M, Fukunishi H, Morita Y, Gostout BS, Stewart EA, MRgFUS Study Group. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril. 2010;93(1):199.

  60. Vilos GA, Allaire C, Laberge P-Y, Leyland N. The Management of Uterine Leiomyomas. J Obstet Gynaecol Can 2015; 37: 157-178. clinical practice guideline

  61. Donnez J, Dolmans M-M. Uterine fibroid management: from the present to the future. Human Reprod Update 2016;1-22. Revisión




2020     |     www.medigraphic.com